Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

Kennedy Jr, a vocal vaccine skeptic and activist lawyer, was confirmed Thursday as the nation’s new health secretary. The Senate voted largely alo ...

(HealthDay News) — Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical Association.

HealthDay News — A federal judge has ordered the US Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) to restore access to public health websites that were ...

HealthDay News — For infants born before 34 weeks of gestation and with a birth weight less than 1000g, probiotics used in neonatal units are associated with reduced mortality, according to a study ...

Use of one or more classes of medications for secondary CVD prevention peaked at 43.1 percent, decreased to 31.3 percent ...

Study identifies potential treatment strategy for high-threshold peanut allergy; Emblaveo approved for complicated intra-abdominal ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

The tablet formulation can either be swallowed whole or dispersed in a teaspoon of filtered (non-chlorinated) water.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.